A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

NCT00418665 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Thrombocytopenia

Interventions

BIOLOGICAL: AMG 531
DRUG: Placebo

Sponsor

Amgen